Fig. 6

TRNT using ¹⁷⁷Lu-labelled sdAb 2F8. a Tumour volumes (cm³) for mice as a function of time (days post-injection), data are expressed as mean ± SD (graph showing the mice individually is presented in Additional file 1: Fig. 3). b Resulting survival curves of the different treatment groups (n = 10, tumour inoculation on day 20). Mice injected with vehicle reached tumours > 1 cm³ between 21 and 47 days (based on individual analyses). Animals treated with three radioactive doses of 9.3 MBq ¹⁷⁷Lu-DTPA-sdAb 2F8 had tumours exceeding 1 cm³ from day 28 onwards, resulting in a median survival of 62 days post-MM cancer cell inoculation. Animals receiving 18.5 MBq ¹⁷⁷Lu-DTPA-2F8 three times surpassed a tumour size > 1 cm³ from 50 days onwards, and survival was significantly longer (p < 0.0002, log-rank Mantel–Cox test) with a median survival of 65.5 days. Median survival in both groups receiving ¹⁷⁷Lu-DTPA-2F8 was significantly longer than that for animals receiving vehicle solution (* p < 0.0332, *** p < 0.0002, log-rank Mantel–Cox test). c Tumour size comparison at day 23 post-first treatment (or day 43 post-inoculation of MM cancer cells). Data shown are mean ± SD. (ns: not significant, ** p < 0.005, using one-way ANOVA, Tukey’s multiple comparison test). d Weight progression of the different treated groups. Data are expressed as mean ± SD